Table 3. Alcohol-based experiments .
| Addictive drug | Manipulation | Target | Subjects | Main findings/ References |
| Alcohol | Suvorexant | dual OX1/2R | R (rat) | Reduced the latency to REM sleep and sleep and slow-wave-sleep (SWS) onset in a dose-dependent manner/produced REM sleep and SWS fragmentation85 |
| Almorexant | dual OX1/2R | Healthy humans | Almorexant did not affect the pharmacokinetics of ethanol and did not synergize its effects86 | |
| Almorexant | dual OX1/2R | R | Diminished alcohol self-administration (Systemic or VTA administration)79 | |
| Almorexant | dual OX1/2R | R | It did not enhance the sedative effect of alcohol87 | |
| SB-334867 | OX1R | R | Reduced alcohol intake and preference (Intra-NAc infusions)80 | |
| SB-334867 | OX1R | R | Decreased alcohol relapse drinking83 | |
| SB-334867 | OX1R | R | Attenuated ethanol self-administration and the cue-induced reinstatement of ethanol–seeking in highly motivated rats 82 | |
| GSK1059865 | OX1R | M (mice) | Significantly reduced alcohol consumption in ethanol-dependent Mice84 | |
| TCS-OX2-29 | OX2R | R | Microinjections of TCS-OX2-29 (into the aPVT) reduced intermittent-access ethanol drinking81 |